[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-435817-105":59,"doc-detail-435817-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-randomized-trial-of-sentinel-node-biopsy-omission-after-neoadjuvant-systemic-therapy-in-clinically-node-negative-or-selected-node-positive-breast-cancer-study-protocol","A Randomized Trial of Sentinel Node Biopsy Omission After Neoadjuvant Systemic Therapy in Clinically Node-Negative or Selected Node-Positive Breast Cancer - Study Protocol","","Axillary surgery is increasingly omitted in early-stage breast cancer, but neoadjuvant studies have mainly focused on small single-arm cohorts with highly selected patients and confirmed pathologic complete response. The NeoNAUTILUS trial evaluates oncologic safety of omitting sentinel lymph node biopsy in patients with a high likelihood of axillary pathologic complete response after neoadjuvant systemic therapy, irrespective of breast pCR status. The prospective multicenter randomized controlled noninferiority trial enrolls eligible women across 12 tertiary centers in Korea.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-randomized-trial-of-sentinel-node-biopsy-omission-after-neoadjuvant-systemic-therapy-in-clinically-node-negative-or-selected-node-positive-breast-cancer-study-protocol/435817/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-randomized-trial-of-sentinel-node-biopsy-omission-after-neoadjuvant-systemic-therapy-in-clinically-node-negative-or-selected-node-positive-breast-cancer-study-protocol/435817.png","ImageObject",300,407,{"name":92,"@type":93},"moss~","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-29",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What question does the NeoNAUTILUS trial address?","Question",{"text":112,"@type":113},"Whether sentinel lymph node biopsy can be omitted after neoadjuvant systemic therapy in patients with a high probability of axillary pCR, regardless of breast pCR status.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Who is eligible to participate in the trial?",{"text":117,"@type":113},"Women with clinical T1–T3, N0, or selected N1 invasive breast cancer who completed neoadjuvant systemic therapy and are candidates for breast-conserving surgery.",{"name":119,"@type":110,"acceptedAnswer":120},"How is the trial designed?",{"text":121,"@type":113},"A prospective multicenter randomized controlled noninferiority trial conducted at 12 tertiary centers in Korea.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},435817,1790817656,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","J Breast Cancer. 2025 Dec;28(6):437-447 [https://doi.org/10.4048/jbc.2025.0157](https://doi.org/10.4048/jbc.2025.0157)[ ](https://doi.org/10.4048/jbc.2025.0157)pISSN 1738-6756·eISSN 2092-9900  \nStudy Protocol  \nReceived: Jun 30, 2025  \nRevised: Aug 21, 2025  \nAccepted: Oct 20, 2025  \nPublished online: Nov 14, 2025  \nCorrespondence to  \nWonshik Han  \nDepartment of Surgery, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea.  \nEmail: [hanw@snu.ac.kr](hanw@snu.ac.kr)  \n© The Authors 2025  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://](https://)[ ](https://)[creativecommons.org/licenses/by-nc/4.0/](creativecommons.org/licenses/by-nc/4.0/)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nORCID iDs  \nJi-Jung Jung  [https://orcid.org/0000-0003-4080-1075](https://orcid.org/0000-0003-4080-1075)[ ](https://orcid.org/0000-0003-4080-1075)Hee Jeong Kim  [https://orcid.org/0000-0002-1343-8138](https://orcid.org/0000-0002-1343-8138)[ ](https://orcid.org/0000-0002-1343-8138)Byung Joo Chae  [https://orcid.org/0000-0003-1564-0978](https://orcid.org/0000-0003-1564-0978)[ ](https://orcid.org/0000-0003-1564-0978)[Eun-Kyu Kim](Eun-Kyu Kim)  [https://orcid.org/0000-0003-1318-0939](https://orcid.org/0000-0003-1318-0939)[ ](https://orcid.org/0000-0003-1318-0939)Jee Hyun Ahn  [https://orcid.org/0000-0003-4176-3277](https://orcid.org/0000-0003-4176-3277)[ ](https://orcid.org/0000-0003-4176-3277)Joon Jeong  [https://orcid.org/0000-0003-0397-0005](https://orcid.org/0000-0003-0397-0005)[ ](https://orcid.org/0000-0003-0397-0005)Seeyoun Lee  [https://orcid.org/0000-0002-7576-1512](https://orcid.org/0000-0002-7576-1512)  \nA Randomized Trial of Sentinel Node Biopsy Omission After Neoadjuvant Systemic Therapy in Clinically Node-Negative or Selected Node-Positive Breast Cancer  \nJi-Jung Jung  1, Hee Jeong Kim  2, Byung Joo Chae  3, Eun-Kyu Kim  4, Jee Hyun Ahn  5, Joon Jeong  6, Seeyoun Lee  7, Seung Pil Jung  8, Joohyun Woo  9, Junwon Min  10, Jong-Ho Cheun  11, Min Sung Chung  12, Kyung Hwan Shin  13, Jung Min Chang  14, Woo Kyung Moon  14,  \nWonshik Han  1,15,16  \n1Department of Surgery, Seoul National University College of Medicine, Seoul, Korea  \n2Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea 3Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea  \n4Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea  \n5Department of Surgery, Yonsei University College of Medicine, Seoul, Korea  \n6Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea 7Department of Surgery, Center for Breast Cancer, National Cancer Center, Goyang, Korea  \n8Department of Surgery, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea  \n9Department of Surgery, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Korea  \n10Department of Surgery, Dankook University College of Medicine, Cheonan, Korea  \n11Department of Surgery, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea  \n12Department of Surgery, Hanyang University College of Medicine, Seoul, Korea  \n13Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea 14Department of Radiology, Seoul National University College of Medicine, Seoul, Korea  \n15Cancer Research Institute, Seoul National University, Seoul, Korea  \n16Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea  \nABSTRACT  \nPurpose: Axillary surgery is increasingly omitted in patients with early-stage breast cancer undergoing upfront surgery, as supported by trials such as ","cbCaiknudpfX9YGI","https://ap.wps.com/l/cbCaiknudpfX9YGI","pdf",1933392,11,"English","# Abstract\n## Purpose\n## Methods","[{\"question\":\"What question does the NeoNAUTILUS trial address?\",\"answer\":\"Whether sentinel lymph node biopsy can be omitted after neoadjuvant systemic therapy in patients with a high probability of axillary pCR, regardless of breast pCR status.\"},{\"question\":\"Who is eligible to participate in the trial?\",\"answer\":\"Women with clinical T1–T3, N0, or selected N1 invasive breast cancer who completed neoadjuvant systemic therapy and are candidates for breast-conserving surgery.\"},{\"question\":\"How is the trial designed?\",\"answer\":\"A prospective multicenter randomized controlled noninferiority trial conducted at 12 tertiary centers in Korea.\"}]","A Randomized Trial of Sentinel Node Biopsy Omission After Neoadjuvant Systemic Therapy in Clinically Node-Negative or Selected Node-Positive Breast Cancer - Study Protocol | PDF",1790675410,28]